Literature DB >> 20210238

Prognostic relevance of MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer patients.

Antonio Russo1, Paola Sala, Paola Alberici, Isabella Gazzoli, Paolo Radice, Claudia Montefusco, Margherita Torrini, Cristina Mareni, Mara Fornasarig, Manuela Santarosa, Alessandra Viel, Piero Benatti, Monica Pedroni, Maurizio Pedroni, Maurizio Ponz de Leon, Emanuela Lucci-Cordisco, Maurizio Genuardi, Luca Messerini, Vittoria Stigliano, Alessandro Cama, Maria Cristina Curia, Laura de Lellis, Stefano Signoroni, Marco A Pierotti, Lucio Bertario.   

Abstract

AIMS AND
BACKGROUND: Colorectal carcinoma patients from hereditary non-polyposis colorectal cancer families are suggested to have a better prognosis than sporadic colorectal carcinoma cases. Since the majority of hereditary non-polyposis colorectal cancer-related colorectal carcinomas are characterized by microsatellite instability due to germline mutations in DNA mismatch repair genes, this is consistent with the prolonged survival observed in sporadic microsatellite instability-positive colorectal carcinoma compared to microsatellite stable cases. However, a fraction of colorectal carcinoma cases belongs to families that, despite fulfilling the clinical criteria for hereditary non-polyposis colorectal cancer, do not carry mismatch repair gene mutations. Our aim was to verify to what extent the genotypic heterogeneity influences the prognosis of hereditary non-polyposis colorectal cancer patients.
METHODS: A survival analysis was performed on 526 colorectal carcinoma cases from 204 Amsterdam Criteria-positive hereditary non-polyposis colorectal cancer families. Enrolled cases were classified as MLH1-positive, MSH2-positive and mutation-negative, according to the results of genetic testing in each family.
RESULTS: Five-year survival rates were 0.73 (95% CI, 0.66-0.80), 0.75 (95% CI, 0.66-0.84) and 0.62 (95% CI, 0.55-0.68) for MLH1-positive, MSH2-positive and mutation-negative groups, respectively (logrank test, P = 0.01). Hazard ratio, computed using Cox regression analysis and adjusted for age, sex, tumor site and stage, was 0.71 (95% CI, 0.51-0.98) for the mutation-positive compared to the mutation-negative group. Moreover, in the latter group, patients with microsatellite instability-positive colorectal carcinomas showed a better outcome than microsatellite stable cases (5-year survival rates, 0.81 and 0.60, respectively; logrank test, P = 0.006).
CONCLUSIONS: Our results suggest that the prognosis of hereditary non-polyposis colorectal cancer-related colorectal carcinoma patients depends on the associated constitutional mismatch repair genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20210238     DOI: 10.1177/030089160909500616

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Prognostic significance of hMLH1/hMSH2 gene mutations and hMLH1 promoter methylation in sporadic colorectal cancer.

Authors:  Yibaina Wang; Dandan Li; Xia Li; Chong Teng; Lin Zhu; Binbin Cui; Yashuang Zhao; Fulan Hu
Journal:  Med Oncol       Date:  2014-06-11       Impact factor: 3.064

2.  Exo1 independent DNA mismatch repair involves multiple compensatory nucleases.

Authors:  Amar Desai; Stanton Gerson
Journal:  DNA Repair (Amst)       Date:  2014-07-15

3.  Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?

Authors:  Elena Maccaroni; Raffaella Bracci; Riccardo Giampieri; Francesca Bianchi; Laura Belvederesi; Cristiana Brugiati; Silvia Pagliaretta; Michela Del Prete; Mario Scartozzi; Stefano Cascinu
Journal:  Oncotarget       Date:  2015-11-17

Review 4.  Familial Colorectal Cancer Type X.

Authors:  Diana Bregner Zetner; Marie Luise Bisgaard
Journal:  Curr Genomics       Date:  2017-08       Impact factor: 2.236

5.  Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis.

Authors:  Jiang-Tao Hou; Li-Na Zhao; Ding-Jun Zhang; Dong-Yong Lv; Wei-Ling He; Bin Chen; Hui-Biao Li; Pei-Ru Li; Li-Zhen Chen; Xin-Lin Chen
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.